On November 6, Hims & Hers Health Inc. rose 6.36% in Pre-Market Trading, trading at $25.8749 per share, with turnover of $3.6971 million.

The move aligns with renewed focus on the company’s upcoming quarterly results due on November 9, with consensus expecting revenue of $893 million, up 53.88% year over year, and EPS of $0.07. That earnings setup appears to be helping offset pressure from the ongoing FTC complaint and subscription billing dispute.

Background context shows the company’s prior quarter delivered $753 million in revenue, up 38.25% year over year, while gross margin was 63.83%. Investors have also been weighing expansion initiatives in Australia against compliance-related concerns tied to alleged misleading sales practices and charges for unwanted subscriptions, which the company has asked a federal judge to dismiss.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)